Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aclaris Therapts (NQ: ACRS )

3.800 -0.520 (-12.04%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aclaris Therapts

< Previous 1 2 3 4 Next >
DocuSign To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Tuesday
Wells Fargo cut the price target for Cheniere Energy, Inc. (NYSE: LNG) from $236 to $230. Wells Fargo analyst Michael Blum maintained an Overweight rating. Cheniere Energy shares fell 4.8% to close at... 
Via Benzinga
Analyst Ratings for Aclaris Therapeutics
Via Benzinga
These 2 Biotech Stocks Made Big Monday Moves
Find out which was the winner and which was the loser. 
Via The Motley Fool
Nasdaq Rises 50 Points; Ciena Earnings Top Expectations
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Monday. The Dow traded up 0.16% to 33,444.91 while the NASDAQ rose 0.43% to 11,739.11. The S&P... 
Via Benzinga
As Focus Shifts From Hidradenitis Suppurativa, Analyst Seems Bullish On Aclaris
Aclaris Therapeutics Inc (NASDAQ: ACRS) flunked a 12-week, Phase 2a study of zunsemetinib (ATI-450) for moderate to severe hidradenitis suppurativa. 
Via Benzinga
Why Aclaris Therapeutics Is Crashing Today
The company announced disappointing results from a phase 2a clinical study. 
Via The Motley Fool
Why Aclaris Therapeutics Stock Is Plunging Today
Via Benzinga
Aclaris Therapeutics's Return On Capital Employed Insights
Via Benzinga
Looking Into Aclaris Therapeutics's Return On Capital Employed
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 36 companies set new 52-week lows. 
Via Benzinga
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch... 
Via Benzinga
Looking Into Aclaris Therapeutics Return On Capital Employed
  
Via Benzinga
Recap: Aclaris Therapeutics Q1 Earnings
Aclaris Therapeutics (NASDAQ:ACRS) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Jumps Over 100 Points; BridgeBio Pharma Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Monday. The Dow traded up 0.42% to 33,531.77 while the NASDAQ rose 0.97% to 11,802.73. The S&P 500... 
Via Benzinga
Nasdaq Rises 50 Points; US Factory Orders Down 1.6% In January
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 33,471.14 while the NASDAQ rose... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Week In Review: Full-Life Acquires Focus-X And Its Eight Radiotherapeutics In $245 Million Deal
Full-Life Technologies, a Brussels-Shanghai radiotherapeutics company, will acquire Focus-X Therapeutics for up to $245 million. Using its proprietary peptide engineering technology, Focus-X has built... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
10 Best Stocks to Buy Now in December
These beaten-down stocks have significant upside. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
Via Benzinga
Aclaris Therapeutics: Q2 Earnings Insights
  Aclaris Therapeutics (NASDAQ:ACRS) reported its Q2 earnings results on Wednesday, August 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2022
Upgrades 
Via Benzinga
Aclaris Therapeutics's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, Aclaris Therapeutics's (NASDAQ:ACRS) reported sales totaled $1.45 million. Despite a 17.61% increase in earnings, the company posted a loss of $18.79... 
Via Benzinga
Airbnb And 3 Other Stocks Insiders Are Selling
Although gold futures traded higher this morning on Tuesday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s... 
Via Benzinga
50 Biggest Movers From Yesterday
Gainers electroCore, Inc. (NASDAQ: ECOR) shares jumped 64% to settle at $0.88 on Wednesday after the company's gammaCore nVNS device received FDA Breakthrough Designation for... 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Rises 50 Points; Jefferies Shares Drop
Toward the end of trading Wednesday, the Dow traded up 0.05% to 36,269.24 while the NASDAQ rose 0.35% to 15,205.90. The S&P also rose, gaining, 0.26% to 4,725.52. The U.S... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Immuron (NASDAQ:IMRN) shares rose 36.6% to $3.58 during Wednesday's regular session. Trading volume for this security as of 12:32 EST is 35.0 million, which is... 
Via Benzinga
Mid-Day Market Update: Crude Oil Rises 2%; Philips Shares Plummet
Midway through trading Wednesday, the Dow traded up 0.26% to 36,346.85 while the NASDAQ rose 0.77% to 15,270.07. The S&P also rose, gaining, 0.57% to 4,739.98. The U.S. has... 
Via Benzinga
28 Stocks Moving In Wednesday's Mid-Day Session
Gainers Immuron Limited (NASDAQ: IMRN) shares jumped 40.2% to $3.5887. Immuron received funding of A$6.2 ($4.45) million from the U.S Department of Defense to examine a dosing... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.